28 May 2020 Amarex Co-Authors Paper on Emergency
Post# of 153886
(Total Views: 968)
Posted On: 05/29/2020 10:32:04 AM
28 May 2020
Amarex Co-Authors Paper on Emergency Use Treatment of Leronlimab for COVID-19
Germantown, MD, USA (May 28, 2020) – In mid-March, Amarex worked with client CytoDyn to
prepare, submit, and achieve FDA approval for emergency use of CytoDyn’s drug leronlimab as
a treatment for severe cases of COVID-19. Since then, over 50 patients in a New York hospital
have been treated with leronlimab. Initial results appear to show that leronlimab restores
immune homeostasis, reduces plasma viral load, and reverses hyperimmune activation and
inflammation in critically ill COVID-19 patients.
Subsequently, Amarex’s staff co-authored a research paper, in conjunction with CytoDyn,
analyzing the results of the leronlimab treatment. The paper is currently in peer-review.
Amarex President & CEO, Dr. Kazem Kazempour, and Senior Vice President of Clinical
Operations, Dr. Kush Dhody, are both contributing authors on the paper. The paper is titled
Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces
Plasma Viral Load in Critical COVID-19, and is available for review at
https://www.researchsquare.com/article/rs-26517/v1.
Amarex simultaneously helped CytoDyn with two 'rush' IND applications in order to more
definitively assess leronlimab’s effectiveness as a COVID-19 treatment in serious COVID-19
cases and in mild-to-moderate COVID-19 cases. Both applications received approval from the
FDA and these studies are currently enrolling subjects. Amarex is providing clinical trial
management services for these trials.
Dr. Kazem Kazempour stated, “Considering the novelty of COVID-19, conducting this initial
research and achieving these results in less than two months is remarkable. The Amarex team is
encouraged by these successes and excited to be directly involved in finding solutions to the
COVID-19 pandemic.”
Amarex Co-Authors Paper on Emergency Use Treatment of Leronlimab for COVID-19
Germantown, MD, USA (May 28, 2020) – In mid-March, Amarex worked with client CytoDyn to
prepare, submit, and achieve FDA approval for emergency use of CytoDyn’s drug leronlimab as
a treatment for severe cases of COVID-19. Since then, over 50 patients in a New York hospital
have been treated with leronlimab. Initial results appear to show that leronlimab restores
immune homeostasis, reduces plasma viral load, and reverses hyperimmune activation and
inflammation in critically ill COVID-19 patients.
Subsequently, Amarex’s staff co-authored a research paper, in conjunction with CytoDyn,
analyzing the results of the leronlimab treatment. The paper is currently in peer-review.
Amarex President & CEO, Dr. Kazem Kazempour, and Senior Vice President of Clinical
Operations, Dr. Kush Dhody, are both contributing authors on the paper. The paper is titled
Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces
Plasma Viral Load in Critical COVID-19, and is available for review at
https://www.researchsquare.com/article/rs-26517/v1.
Amarex simultaneously helped CytoDyn with two 'rush' IND applications in order to more
definitively assess leronlimab’s effectiveness as a COVID-19 treatment in serious COVID-19
cases and in mild-to-moderate COVID-19 cases. Both applications received approval from the
FDA and these studies are currently enrolling subjects. Amarex is providing clinical trial
management services for these trials.
Dr. Kazem Kazempour stated, “Considering the novelty of COVID-19, conducting this initial
research and achieving these results in less than two months is remarkable. The Amarex team is
encouraged by these successes and excited to be directly involved in finding solutions to the
COVID-19 pandemic.”
(1)
(0)